Peers of Gyre Therapeutics Inc (GYRE)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month free cash flow. Values the entire business on cash available after reinvestment.
Latest EV/FCF
-38.34x
As of Oct 9, 2026
Beyond EV/FCF, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/FCF |
|---|---|
| Oct 9, 2026 | -38.34x |
| Oct 8, 2026 | -36.45x |
| Oct 7, 2026 | -38.22x |
| Oct 6, 2026 | -38.47x |
| Oct 5, 2026 | -40.18x |
| Oct 2, 2026 | -38.66x |
| Oct 1, 2026 | -37.97x |
| Sep 30, 2026 | -40.05x |
EV/FCF = Enterprise Value / Free Cash Flow (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/FCF is especially insightful for capital-intensive businesses.
Read the general EV/FCF definition, formula, and analyst usage guide.
EV/FCF guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison